Cargando…
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Andhra Pradesh cohort of the A(1)chieve study
BACKGROUND: The A(1)chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS:...
Autores principales: | Abubaker, Mohammed, Rao, Y Sadasiva, Zargar, Samir Hamid, Shetty, Raman, Shankar, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872908/ https://www.ncbi.nlm.nih.gov/pubmed/24404500 http://dx.doi.org/10.4103/2230-8210.122129 |
Ejemplares similares
-
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North India cohort of the A(1)chieve study
por: Kumar, Surender, et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Karnataka cohort of the A(1)chieve study
por: Deshpande, Neeta, et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A(1)chieve study
por: Majumder, Anirban, et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West India cohort of the A(1)chieve study
por: Jain, Sunil M., et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Tamil Nadu cohort of the A(1)chieve study
por: Shunmugavelu, M., et al.
Publicado: (2013)